Program DescriptionThis CME-certified presentation given by Nancy Moldawer, RN, MSN, delves into key issues faced by oncology nurses caring for patients with renal cell carcinoma (RCC) who are taking targeted therapy to manage their disease. Ms. Moldawer begins with a general overview covering RCC epidemiology, clinical presentation, and treatment options. Whereas surgery is potentially curative for early-stage disease, individuals with advanced RCC have significant treatment needs that are not adequately met by other treatment modalities, such as radiotherapy, chemotherapy, and immunotherapy. To address these unmet needs, intensive research has been devoted to understanding the molecular mechanisms contributing to RCC pathogenesis, particularly the process of angiogenesis, so that rational therapeutic approaches can be developed. Out of these efforts, researchers have developed several therapeutic drugs, including sunitinib, sorafenib, bevacizumab, and temsirolimus, that target various molecular players in the angiogenesis process. Ms. Moldawer reviews each of the aforementioned targeted agents, detailing appropriate dosing and administration, major side effects and toxicities, and strategies for managing these complications. She concludes by discussing several approaches that may be taken by nurses caring for patients on these agents to maximize medication adherence and efficacy and minimize adverse effects.
Target Audience
This activity will be designed for community- and hospital-based medical oncologists, hematologists, urologists, nephrologists, and allied healthcare providers who provide medical care and support to patients with renal cell carcinoma.
Learning Objectives
After completing this program, participants should be able to
| |
• |
Describe the epidemiology, clinical presentation, and treatment options for advanced RCC |
| |
• |
Discuss the use of targeted agents as first- and second-line therapies for RCC |
| |
• |
Recognize major side effects and toxicities related to targeted therapy and appropriate nursing care strategies to manage these complications |
| |
• |
Discuss effective patient education approaches to maximize medication adherence and efficacy and minimize untoward effects |
Faculty
Robert A. Figlin, MD (Activity Director)
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical research
City of Hope Comprehensive Cancer Center
Duarte, California
Nancy P. Moldawer, RN, MSN
Clinical Research Operations Manager
Division of Medical Oncology and Experimental Therapeutics
City of Hope National Medical Center
Duarte, California
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
This activity is designated for .5 AMA Physicians’ Recognition Award™ credits. To receive your CME credits you are requested to review the material in full and take the post-test and evaluation. Your evaluation of the activity and comments will remain confidential.
Disclosure
City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational use of products is provided below.
Robert A. Figlin, MD (Activity Director)
| Commercial Interest |
Relationship |
Amgen, GlaxoSmithKline plc; Keryx
Biopharmaceuticals, Inc.; Pfizer Inc; Wyeth |
Grant/Research Support |
Keryx Biopharmaceuticals, Inc; Pfizer Inc;
Wyeth |
Consultant |
Nancy P. Moldawer RN, MSN
| Commercial Interest |
Relationship |
| Wyeth |
Speakers’ Bureau |
Ms. Moldawer reported the following specific mention of off-label and/or investigational use of products within his presentation.
| Product |
Investigational and/or Off-Label Use |
| Bevacizumab |
Renal cell carcinoma |
| IFN-α |
Renal cell carcinoma |
| Erlotinib |
Renal cell carcinoma |
References
| 1. |
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2:471-478. |
| 2. |
Atkins MB, Ernstoff MS, Figlin RA, et al. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007;13(2 Pt 2):667s-670s. |
| 3. |
Avastin® (bevacizumb) Full Prescribing Information. Genentech, Inc. March 2008. |
| 4. |
Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859-863. |
| 5. |
Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53(5):917-30. Epub 2007 Nov 26. |
| 6. |
Brauch H, Weirich G, Klein B. VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference? Toxicol Lett. 2004;151(1):301-310. |
| 7. |
Brennan JF, Stilmant MM, Babayan RK, Siroky MB. Acquired renal cystic disease: implications for the urologist. Br J. Urol. 1991;67(4):342-348. |
| 8. |
Bukowski RM, Kabbinavar F, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536-4541. |
| 9. |
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638. |
| 10. |
Choueiri TK, Rini B, Garcia JA, et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol. 2007;18:249-255. |
| 11. |
Chow WH, Gridley G, Fraumeni JF Jr, et al. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343(18):1305-1311. |
| 12. |
Chow WH, McLaughlin JK, Linet MS, et al. Use of analgesics and risk of renal cell cancer. Intl J Cancer. 1994;59(4):467-470. |
| 13. |
Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002;1:415-426. |
| 14. |
De Mulder PH. Targeted therapy in metastatic renal cell carcinoma. Ann Oncol. 2007;18:ix98-102. |
| 15. |
Escudier B, Eisen T, Stadler WM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134. |
| 16. |
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111. |
| 17. |
Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol. 1991;145:248-250. |
| 18. |
Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25-35. |
| 19. |
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005;23:7889-7896. |
| 20. |
Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314-319. |
| 21. |
Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res. 2003;9:2882-2886. |
| 22. |
Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health-Syst Pharm. 2008;65:123-131. |
| 23. |
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281. |
| 24. |
Hunt JD, van der Hel OL, McMillan GP, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005 Mar 10;114(1):101-108. |
| 25. |
Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61(Suppl 5):S21-S26. |
| 26. |
Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ. 2001;164:662-670. |
| 27. |
Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843-852. |
| 28. |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66. |
| 29. |
Lee CT, Katz J, Fearn PA. Russo P. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002 Jul-Aug;7(4):135-140. |
| 30. |
Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170(6 Pt 1):2163-2172. |
| 31. |
Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510. |
| 32. |
Lornoy W, Because S, de Vleeschouwer M, et al. Renal cell carcinoma, a new complication of analgesic nephropathy. Lancet. 1986;1(8492):1271-1272. |
| 33. |
Mandel JS, McLaughlin JK, Schlehofer B, et al. International renal-cell cancer study. IV. Occupation. Int J Cancer. 1995;61(5):601-605. |
| 34. |
McLaughlin JK, Blot WJ. A critical review of epidemiology studies of trichloroethylene and perchloroethylene and risk of renal-cell cancer. Int Arch Occup Environ Health. 1997;70(4):222-231. |
| 35. |
Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832-841. |
| 36. |
Moldawer N, Wood LS. Integrating the oncology nurse into the new paradigm of targeted therapy in renal cell cancer: special considerations, initiatives, guidelines. Kidney Cancer J. 2006;4:25-32. |
| 37. |
Moore SH. Online educational activity – 2006. |
| 38. |
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. |
| 39. |
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540. |
| 40. |
Motzer RJ, Escudier B, Oudard S, et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study. J Clin Oncol. 2008;26(May 20 suppl): Abstract LBA5026. |
| 41. |
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524. |
| 42. |
National Cancer Institute website. Search for clinical trials. Available at: http://www.cancer.gov/clinicaltrials/search. Accessed March 19, 2008. |
| 43. |
National Cancer Institute. SEER cancer statistics fact sheet: Cancer of the kidney and renal pelvis. Available at http://seer.cancer.gov/statfacts/html/kidrp.html?statfacts_page=kidrp.html&x=22&y=16. Accessed February 8, 2008. |
| 44. |
National Comprehensive Cancer Network. "Kidney Cancer." NCCN Clinical Practice Guidelines in Oncology 2007;v.1.2008. |
| 45. |
Nexavar® (sorafenib) Full Prescribing Information. Bayer HealthCare. 2008. |
| 46. |
Oregon Health & Science University. Kidney Cancer Program. Available at: http://www.ohsu.edu/health/page.cfm?id=13584. |
| 47. |
Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004;172:2167-2171. |
| 48. |
Patard JJ, Leray E, Rodriguez A, et al. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 2003;2:226-232. |
| 49. |
Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98(13):920-931. |
| 50. |
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512. |
| 51. |
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975_2004/. |
| 52. |
Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. 2008 ASCO Genitourinary Cancers Symposium. Abstract 350. |
| 53. |
Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103:253-262. |
| 54. |
Setiawan VW, Stram DO, Nomura AM, et al. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007;166(8):932-40. Epub 2007 Jul 26. |
| 55. |
Skotnicki JS, Leone CL, Smith AL, et al. Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res. 2001;7(Suppl):3749-3750. |
| 56. |
Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107:1793-1800. |
| 57. |
Sutent® (sunitinib) Full Prescribing Information. Pfizer, Inc. October 2007. |
| 58. |
Torisel™(temsirolimus) Full Prescribing Information. Wyeth Pharmaceuticals, Inc. May 2007. |
| 59. |
Truong LD, Krishnan B, Cao JT, et al. Renal neoplasm in acquired cystic kidney disease. Am J Kidney Dis. 1995;26(1):1-12. |
| 60. |
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/Mek/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109. |
| 61. |
Wood LS. Targeted therapies for advanced renal cell carcinoma: Part I—sunitinib. Oncology Nurs News. 2007;3:19-20. |
| 62. |
Wood LS. Targeted therapies for advanced renal cell carcinoma: Part II—sorafenib. Oncology Nurs News. 2007;4:37-38. |
| 63. |
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. |
| 64. |
Zbar B, Glenn G, Merino M, et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol. 2007 Feb;177(2):461-465. |
| 65. |
Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657. |
Top of the Page>>
|
